The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Home Explore BioSpectrum Asia June 2024
View in Fullscreen

IPO FEVER GRIPS BIOTECH INDUSTRY
After two tumultuous years marred by geopolitical tensions and recession, the biotech
sector IPOs (initial public offering) is showing signs of recovery. Experts are hopeful
that this year will revive the public equity markets for biotech companies. Twelve
biotech companies have gone public this year, raising a total of nearly $1.5 billion,
compared to a total of only nineteen biotech companies, throughout 2023. Are biotech IPOs poised for an upswing? Is the worst finally over for biotech IPOs? Let's find out.

Like this book? You can publish your book online for free in a few minutes!
Share

Related Publications

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2024-05-29 07:32:55

BioSpectrum Asia June 2024

IPO FEVER GRIPS BIOTECH INDUSTRY
After two tumultuous years marred by geopolitical tensions and recession, the biotech
sector IPOs (initial public offering) is showing signs of recovery. Experts are hopeful
that this year will revive the public equity markets for biotech companies. Twelve
biotech companies have gone public this year, raising a total of nearly $1.5 billion,
compared to a total of only nineteen biotech companies, throughout 2023. Are biotech IPOs poised for an upswing? Is the worst finally over for biotech IPOs? Let's find out.

Keywords: biotech IPOs,equity market

"We Communicate directly with Life-Science Leaders and BioPharma Executives World-Wide" For More information , Please contact [email protected] www.biospectrumasia.com www.biospectrumindia.com


Trailblazing Innovation & Collaborations in ADC Drug Development in Asia June 25-27, 2024 | Incheon, South Korea www.worldadc-asia.com Meet 150+ ADC Experts Including: Ziping Wei Chief Executive Officer Bliss Biopharma Tse Wen Chang Founder & Chairman Immunwork Jun Ge Executive Director, Head of China Clinical Development Gilead Heidi Wang Chief Executive Officer OBI Pharma Yasuyuki Kaneta Senior Director Daiichi Sankyo Sun-Hwa Lee Vice Chief Scientific Officer Novelty Nobility ASIA 2024 3rdANNUAL SCAN TO LEARN MORE +1 617 455 4188 @ [email protected] www.worldadc-asia.com Antibody Drug Conjugates World ADC Event Series @World_ADC #WorldADC


Click to View FlipBook Version